CDEK by Data4ThePeople
Sign in Sign up
← All organizations

Akorn, Inc.

For profitContributed to NME

Also known as: Advanced Vision Research | AKORN | Akorn, Inc. | AKORN INC | Akorn Ophthalmic | Oak Pharmaceuticals | OAK PHARMS | OAK PHARMS AKORN | OAK PHARMS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Sep 1, 2004

First marketed drug

Jan 1, 1971

First NDA

May 4, 1984

Last known activity

Jun 9, 2023

Defunct as of May 20, 2020

Timeline

1970s

  1. Jan 1, 1971

    Akorn, Inc.— Founded

1980s

  1. May 4, 1984

    sufentanil— NDA Organization

1990s

  1. Jan 1, 1992

    Taylor Pharmacal— Acquired

  2. Jan 1, 1996

    Pasadena Research Laboratories— Acquired

  3. Apr 26, 1996

    acetaminophen— Marketing Organization

  4. Jan 1, 1998

    Advanced Remedies, Inc— Acquired

2000s

  1. Apr 27, 2007

    azithromycin— NDA Secondary Org

2010s

  1. Jan 1, 2014

    Hi-Tech Pharmacal— Acquired

  2. Jan 1, 2014

    VersaPharm— Acquired

2020s

  1. May 20, 2020

    Akorn, Inc.— Defunct

Drugs by trial phase (9 distinct, 9 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 3 (4 own, 0 via acquisition)

Phase 2 (2 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (165)

Subsidiaries (5 direct, 6 total across the full acquisition tree)

Recent trials (9)

Details

Founded
Abita Springs, LA, US Jan 1, 1971
First NDA
May 4, 1984
Last known activity
Jun 9, 2023

Designations held

  • Priority review

Notes

Acquired by Fresenius